Researchers from Harvard Medical School and Massachusetts General Hospital have developed a new device that produces nitric oxide from an electric spark, making treatment affordable and easy for those with persistent pulmonary hypertension. Under certain conditions, this device could replace the current technology that is both costly and cumbersome.
Treatment with inhaled nitric oxide (NO) has proved to be lifesaving in newborns, children, and adults with several dangerous conditions. But the availability of the treatment has been limited by the size, weight, and complexity of equipment needed to administer the gas, and the therapy’s high price.
Now a research team led by Warren M. Zapol, the Reginald Jenney Professor of Anaesthesia at Harvard Medical School and Massachusetts General Hospital (MGH), has developed a lightweight, portable system that produces NO from the air by means of an electrical spark. Zapol, who pioneered the use of inhaled nitric oxide, is the senior author of a report on the system, which is described by MGH investigators in the July 1 issue of Science Translational Medicine.
“Nitric oxide is used to treat about 35,000 hospitalized U.S. patients each year — mostly adults with pulmonary hypertension and infants with a condition called persistent pulmonary hypertension of the newborn (PPHN),” said Zapol, director of the MGH Anesthesia Center for Critical Care Research and emeritus chief of anesthesia and critical care at the hospital.
“But NO therapy is very expensive — here at MGH, five days’ treatment of a newborn with PPHN costs around $14,000 — and current systems use gas delivered in heavy tanks, making ambulatory treatment impractical,” he explained. “Our new system can economically make NO from the nitrogen and oxygen in the air using only small amounts of electric power. This device could enable trials of NO to treat patients with chronic lung diseases and certain kinds of heart failure, and would make NO therapy available in parts of the world that don’t have the resources that are currently required.”
Not to be confused with the anesthetic gas nitrous oxide, nitric oxide was long considered to be only a toxic pollutant gas. But in the mid-1980s, three U.S. investigators discovered that NO is a signal-transmitting molecule naturally used by the pulmonary, cardiac, and other systems — a discovery that received the 1998 Nobel Prize. Among its many functions, NO relaxes muscles surrounding blood vessels, which reduces blood pressure — a property that led Zapol and his colleagues to investigate its use to treat hypertension in vessels supplying the lungs. Their discovery that inhaled NO selectively relaxed pulmonary vessels without producing a systemic drop in blood pressure led to the therapy’s FDA approval in 1999 for the treatment of PPHN and other lung diseases in newborns. In 2003, Zapol and his former research fellow Claes Frostell received the Inventor of the Year award from the Intellectual Property Owners Association for the development of a system to safely deliver inhaled NO.
Since its FDA approval, NO has been supplied to hospitals in large tanks of compressed gas and administered through bulky and complex delivery devices by trained respiratory therapists. However, in 1992, Zapol and MGH were issued a patent for a system his team had developed to produce NO — which can be naturally produced by lightning bolts — from air by means of an electrical spark.
Although the discovery was licensed by two medical and industrial gas companies, the technology was never developed, possibly because the medical use of inhaled NO was only beginning to be accepted. In addition, the system originally invented by the MGH team was still too large for use in outpatient settings. The growing therapeutic use of NO — along with technological advances including the availability of miniaturized electronic circuitry — allowed the MGH team to develop the system described in the current report.
The investigators designed and built two prototype systems: in one, the NO generator is a separate “offline” system continually generating gas that is delivered into a ventilation system via tubing; the second, an “inline” system, is incorporated into the ventilation system in a way that synchronizes the generation of NO during inhalation with the pulsed delivery of oxygen and other gases to be inhaled, reducing the NO that would be lost during exhalation. Because generation of NO by an electric spark can also produce the toxic gases nitrogen dioxide and ozone, along with metal fragments from the electrode, both systems use calcium hydroxide and air filters to absorb and remove those byproducts.
A series of experiments helped the team determine the best metal to use for the electrode — iridium — and the optimal timing and number of electric sparks. Testing in an animal model revealed that the electrically generated NO produced by both systems was as effective as tank-delivered gas in relieving pulmonary hypertension. Although a gas mixture containing 50 percent oxygen produced the highest NO levels, the amount produced from ambient air was sufficient for therapeutic use. Both systems continued to deliver therapeutic levels of NO for up to 10 days, and subsequent experiments with the inline system not included in this report have continued for up to 28 days. There’s no reason to think the system could not stably produce NO for even longer periods of time, noted Zapol.
“It’s amazing how long this system continues to make NO,” he said. “Once we’ve shown that this [system] can safely be used in human patients with pulmonary hypertension — and we’ve got a clinical trial in progress right now — we’ll be able to conduct studies of inhaled NO delivered in ambulatory settings, including patients’ homes, to treat chronic pulmonary hypertension, right-sided heart failure, and chronic obstructive pulmonary disease.”
Publication: Binglan Yu, et la., “Producing nitric oxide by pulsed electrical discharge in air for portable inhalation therapy,” Science Translational Medicine, 01 Jul 2015: Vol. 7, Issue 294, pp. 294ra107; DOI: 10.1126/scitranslmed.aaa3097
Source: Sue McGreevey, Massachusetts General Hospital Public Affairs